# Allozyne

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allozyne

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.allozyne.com
- Total disclosed funding: $21M
- Latest round: Series B (Oct 19, 2007)
- Investors on record: 6

## About

Allozyne, Inc. is a biotechnology company focused on developing innovative therapeutics and solutions aimed at addressing unmet medical needs in various therapeutic areas.Founded in 2004 in Seattle, US, Allozyne, Inc. specializes in biotechnology solutions. The company was acquired by MedImmune, Inc. in September 2014 for USD 5.5 mn. The company has participated in five deals, with its latest funding round being an Add-on, LP Direct, Trade Sale, bringing its total amount raised to USD 18.00 mn.Allozyne, Inc. provides innovative therapeutic solutions designed to meet the needs of its diverse clientele. Its product offerings include advanced therapeutics aimed at enhancing treatment efficacy across multiple therapeutic areas. The company serves a variety of customers, ranging from small startups to large enterprises globally, including in North America, Europe, and Asia-Pacific, ensuring high-quality service and robust support.The company's revenue is generated through a combination of direct sales to clients and partnerships in the biotechnology sector. The revenue model typically involves multi-year contracts, allowing for predictable revenue streams. This structure supports long-term partnerships, with a focus on maintaining customer satisfaction and retention.Allozyne, Inc. aims to expand its product portfolio with new therapeutics anticipated for release following ongoing research initiatives. Plans include market expansion into Europe and Asia-Pacific within the next two years. The recent acquisition by MedImmune for USD 5.5 mn will bolster these initiatives, providing resources necessary for product development and market penetration.

## Funding rounds

- Series B, Oct 19, 2007, $18M — ARCH Venture Partners, OVP Venture Partners, Alexandria Venture Investments, Amgen Ventures, MPM BioImpact, Accelerator Life Science Partners
- Series A, Oct 11, 2005, $3.4M — ARCH Venture Partners, OVP Venture Partners, Amgen Ventures, MPM BioImpact, Accelerator Life Science Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- OVP Venture Partners (https://capitalatlas.ai/funds/ovp-venture-partners) — Series A, Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B